Monthly oral dosing of islatravir improves tissue distribution for HIV-1 pre-exposure prophylaxis, suggesting its potential as an NRTTI.
The favorable tissue distribution of islatravir and islatravir-triphosphate following oral administration supports the evaluation of NRTTIs for HIV-1 pre-exposure prophylaxis.
No takes yet. Share an insight, caveat, or question.
Hendrix et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: